Antibiotic | Patients | Dose | Renal replacement modalities | Pharmacokinetic data | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
RRT | Dialyzer | Q B(mL/min) | Q UF(mL/min) | Q DF(mL/h) | C max(mg/L) | t H(h) | Vd(l/kg) | AUC (mg·h/L) | CL tot (mL/min) | CL RRT(mL/min) | Sc/Sa | Ref. | |||
Cefepime | 4 | 2 g q8h | CVVH or CVVHD | PAN or PS | 140-250 | 16.7-35 | 500-1000 | 100.5 l | 4.6 | 0.6 | 111.5 | 27.2 | 0.76 | [67] | |
5 | 1-4 g q12h or q24h | CVVH | PAN | 150 | 16 | 44.6 - 94.9 | 12.9 | 0.46 | 834.7 -1,677.8 | 35.9 | 13 | 0.86 | [66] | ||
7 | 1-4 g q12h or q24h | CVVHDF | PAN | 150 | 17 | 857-1020 | 25.7 -90.8 | 8.6 | 0.34 | 344.9 -1,306.8 | 46.8 | 26 | 0.78 | ||
8 | 2 g q12h | CVVH or CVVHDF | AN69 | 150 | 25.7* | 1610* | 43 | 6.17 | 0.55 | 379 | 72.8* | [84] | |||
Ceftazidime | 12 | 2 g q8h | CVVH | PS | 143 | 47 | 58.2 | 4.3 | 0.52* | 344 | 98.7 | 32.1 | 0.69 | [70] | |
7 | 3 g q24h | CVVDHF | AN69 | 150 | 25 | 1000 | 4 | 0.27* | 2514 | 62 | 33.6 | 0.81 | [69] | ||
4 | 1-2 g q6h | CVVH or CVVHDF | AN69 or PS | 130-140 | 25 | 500-1000 | 53.9-112 | 6.4 | 0.67 | 35.5-333.8 | 5-65.6 | 0.93 | [82] | ||
12 | 2 g q12h | CVVH or CVVHDF | AN69 | 150 | 25.7* | 1610* | 78 | 7.74 | 0.37 | 536 | 36.4* | [84] | |||
Meropenem | 8 | 500 mg q12h | CVVH | AN69 | 10 | 26.7 | 39.5 | 3.63 | 105.3 | 82.94 | 24.42 | 0.91 | [71] | ||
5 | 1 g q12h | CVVH | AN69 | 150 | 16.7–33.3 | 5.16 | 0.39* | 246 | 4.3 | 1.96 | 0.93 | [86] | |||
5 | 1 g q12h | CVVDHF | AN69 | 150 | 16.7 – 25 | 1000-1500 | |||||||||
10 | 1 g q8h | High volume CVVH | AN69 | 250 | 66.7-100 | 56.6 | 4.3 | 0.2 | 166.5 | 100 | 58.3 | 0.93 | [72] | ||
15 | 0.5-1 g q8h or q12h | CVVHDF | AN 69 | 90-150 | 0.17-4.5 | 600-1500 | 5.1 | 0.47* | 75 | 26.7 | 0.65 | [87] | |||
5 | 0.5 g q12h | CVVH | PAN | 200 | 25-30 | 24.5 | 6.37 | 0.37 | 129.5 | 4.57 | 1.03 | 0.63 | [88] | ||
9 | 0.5 g q8h or q12h | CVVH | AN69 | 150-170 | 1.7-2.5 | 38.9 | 8.7 | 0.17* | 52 | 22 | 1.17 | [72] | |||
9 | 1 g Stat | CVVH | PS | 150 | 45.8 | 28.1 | 0.37* | 118 | 143.7 | 49.7 | 0.24 | [89] | |||
Piperacillin/ tazobactam | 6 | 4 g q12h/0.5 g q12h | CVVH | PS | 100 | 13.3 | 7.7/13.9 | 64.8/40.3 | [90] | ||||||
CVVHDF | 1000 | 6.7/11.6 | 84.3/52.2 | ||||||||||||
2000 | 6.1/9.4 | 91.3/62.5 | |||||||||||||
8 | 2 g/0.25 g or 4 g/0.5 g | CVVHD | AN69 | 150 | 1.3-3.3 | 1500 | 4.3/5.6 | 0.31/0.24 | 47/29.5 | 22/17 | 0.87/0.64 | [91] | |||
Ceftriaxone | 6 | 2-4 g q24h | CVVH | PA | 100-150 | 20-30 | 10.8 | 0.45* | 16.6 | 0.69 | [77] | ||||
Flucloxacillin | 10 | 4 g q8h | CVVH | PA | 169 | 57 | 139.1-179.7 | 4.9 | 0.69* | 568 | 117.2 | 0.21 | [79] |